Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice

Biochemical and Biophysical Research Communications

Volumn 406, Issue 4, 2011, Pages 614-620

  Shigekawa, Minoru ^a   Takehara, Tetsuo ^a   Kodama, Takahiro ^a   Hikita, Hayato ^a   Shimizu, Satoshi ^a   Li, Wei ^a   Miyagi, Takuya ^a   Hosui, Atsushi ^a   Tatsumi, Tomohide ^a   Ishida, Hisashi ^a   Kanto, Tatsuya ^a   Hiramatsu, Naoki ^a   Hayashi, Norio ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Acute phase proteins; Hepatic stellate cells; Liver fibrosis; STAT3

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; HAPTOGLOBIN; INTERLEUKIN 6; SERUM AMYLOID A; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BILE DUCT LIGATION; CELL FUNCTION; CELL ISOLATION; FIBROGENESIS; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL;

ACUTE-PHASE PROTEINS; ANIMALS; CHOLESTASIS; DISEASE PROGRESSION; HAPTOGLOBINS; HEPATIC STELLATE CELLS; INTERLEUKIN-6; LIVER CIRRHOSIS; MICE; MICE, KNOCKOUT; SERUM AMYLOID A PROTEIN; STAT3 TRANSCRIPTION FACTOR;

MUS;

EID: 79953027387     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.105     Document Type: Article

References (21)

1. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
2. Akira S., Nishio Y., Inoue M., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77:63-71.
3. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
4. Takeda K., Noguchi K., Shi W., et al. Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 1997, 94:3801-3804.
5. Li W., Liang X., Kellendonk C., et al. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J. Biol. Chem. 2002, 277:28411-28417.
6. Haga S., Terui K., Zhang H.Q., et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J. Clin. Invest. 2003, 112:989-998.
7. Inoue H., Ogawa W., Ozaki M., et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 2004, 10:168-174.
8. Sakamori R., Takehara T., Ohnishi C., et al. Signal transducer and activator of transcription 3 signaling within hepatocytes attenuates systemic inflammatory response and lethality in septic mice. Hepatology 2007, 46:1564-1573.
9. Sander L.E., Sackett S.D., Dierssen U., et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 2010, 207:1453-1464.
10. Plum W., Tschaharganeh D.F., Kroy D.C., et al. Lack of glycoprotein 130/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis. Am. J. Pathol. 2010, 176:2236-2246.
11. Mair M., Zollner G., Schneller D., et al. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology 2010, 138:2499-2508.
12. Takeda K., Kaisho T., Yoshida N., et al. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific STAT3-deficient mice. J. Immunol. 1998, 161:4652-4660.
13. Takehara T., Tatsumi T., Suzuki T., et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004, 127:1189-1197.
14. Kountouras J., Billing B.H., Scheuer P.J. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br. J. Exp. Pathol. 1984, 65:305-311.
15. Hikita H., Takehara T., Shimizu S., et al. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010, 52:1310-1321.
16. Kodama T., Takehara T., Hikita H., et al. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 2010, 138:2487-2498.
17. Wuestefeld T., Klein C., Streetz K.L., et al. Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. Hepatology 2005, 42:1082-1090.
18. Canbay A., Feldstein A.E., Higuchi H., et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003, 38:1188-1198.
19. Canbay A., Taimr P., Torok N., et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest. 2003, 83:655-663.
20. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999, 340:448-454.
21. Luchtefeld M., Schunkert H., Stoll M., et al. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J. Exp. Med. 2007, 204:1935-1944.